Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

124.42 +5.18 (+4.34%)
Streaming Delayed Price Updated: 1:07 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 409,558
Open 121.84
Bid (Size) 124.42 (6)
Ask (Size) 124.74 (6)
Prev. Close 119.24
Today's Range 120.07 - 124.66
52wk Range 99.06 - 134.17
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone. 
Via Benzinga
Exposures Product Safety
UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy
Via Benzinga
Topics Cannabis
Exposures Cannabis

Performance

YTD
-1.98%
-1.98%
1 Month
+9.99%
+9.99%
3 Month
+8.80%
+8.80%
6 Month
+17.92%
+17.92%
1 Year
+5.20%
+5.20%

More News

Read More
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
Via Benzinga
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
Via Chartmill
In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
Via The Motley Fool
Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts
Via Benzinga
Despite its impressive fundamentals, NASDAQ:JAZZ remains undervalued.
Via Chartmill
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Via Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms
Via Benzinga
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals
Via Benzinga
How Is The Market Feeling About Jazz Pharmaceuticals?
Via Benzinga
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Via Benzinga
'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine
Via Benzinga
The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
Via Benzinga
In a market where value is scarce, NASDAQ:JAZZ offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
The 3 Best Cannabis Stocks to Buy in August 2024
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
3 Biotech Stocks to Buy on the Dip: July 2024
Via InvestorPlace
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
Via Investor's Business Daily
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Via InvestorPlace
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
Via Benzinga
Topics Cannabis
Exposures Cannabis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.